BYLieve
Phase 2 Completed
383 enrolled 16 charts
RWE About QOL and Compliance of Patients With OFS in China
Completed
562 enrolled
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Phase 2 Completed
327 enrolled
AMALEE
Phase 2 Completed
376 enrolled 17 charts
RIGHT Choice
Phase 2 Completed
222 enrolled 17 charts
NEOLETRIB
Phase 2 Completed
85 enrolled
TP-II
Phase 2 Completed
257 enrolled
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Phase 2 Completed
55 enrolled 15 charts
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Phase 3 Completed
1,803 enrolled 20 charts
COMPLEEMENT-1
Phase 3 Completed
3,246 enrolled 11 charts
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Phase 3 Completed
1,099 enrolled
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Phase 3 Completed
188 enrolled
SAFIA
Phase 3 Completed
354 enrolled
BOOSTER
Phase 2 Completed
160 enrolled
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
Phase 2 Completed
24 enrolled
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Phase 1 Completed
7 enrolled 8 charts
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Phase 3 Completed
502 enrolled 20 charts
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Phase 3 Completed
345 enrolled 9 charts
S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase 3 Completed
257 enrolled 8 charts
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Phase 2 Completed
35 enrolled 11 charts
Study to Compare Zoladexâ„¢ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
Phase 3 Completed
222 enrolled 13 charts
POF
Phase 3 Completed
98 enrolled
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
Phase 2 Completed
Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Phase 3 Completed
416 enrolled
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
Phase 3 Completed
1,000 enrolled
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
Phase 3 Completed
400 enrolled
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
Phase NA Completed
150 enrolled
Combination Chemotherapy in Treating Women With Breast Cancer
Phase 3 Completed
446 enrolled
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
Phase 3 Completed
197 enrolled 23 charts
Zoladex Plus Tamoxifen in Breast Cancer
Phase NA Completed
100 enrolled
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC
Phase 2 Completed
78 enrolled
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
Phase 2 Completed
98 enrolled 13 charts
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
Phase 2 Completed
45 enrolled
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
Phase 2 Completed
170 enrolled